Table 1 Marker expression on tumor tissues in patients with stage II/III CRC treated with 5-FU/FA vs 5-FU/FA/irinotecan
| Â | Total study population | 5-FU/FA/irinotecan | 5-FU/FA |
|---|---|---|---|
| Â | n = 269 | n = 136 (50.6%) | n = 133 (49.4%) |
AREG | 185 | 94 | 91 |
negative | 164 (88.6%) | 84 (89.4%) | 80 (87.9%) |
positive | 21 (11.4%) | 10 (10.6%) | 11 (12.1%) |
EREG | 183 | 90 | 93 |
negative | 143 (78.1%) | 69 (76.7%) | 74 (79.6%) |
positive | 40 (21.9%) | 21 (23.3%) | 19 (20.4%) |
VEGF-C | 204 | 106 | 98 |
negative | 91 (44.6%) | 51 (48.1%) | 40 (40.8%) |
positive | 113 (55.4%) | 55 (51.9%) | 58 (59.2%) |
VEGF-D | 203 | 106 | 97 |
negative | 61 (30%) | 35 (33%) | 26 (26.8%) |
positive | 142 (70%) | 71 (77%) | 71 (73.2%) |
VEGFR-3 | 202 | 103 | 99 |
negative | 115 (56.9%) | 57 (55.3%) | 58 (58.6%) |
positive | 87 (43.1%) | 46 (44.7%) | 41 (41.4%) |
Hif-1 alpha | 115 | 62 | 53 |
negative | 91 (79.1%) | 49 (79%) | 42 (79.2%) |
positive | 24 (20.9%) | 13 (21%) | 11 (20.8%) |
PTEN | 122 | 64 | 58 |
negative | 74 (60.7%) | 38 (59.4%) | 36 (62.1%) |
positive | 48 (39.3%) | 26 (40.6%) | 22 (37.9%) |